

FOI2975

24th April 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	8
1.2 Apalutamide (Erleada)	0
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	6
1.4 Darolutamide (Nubeqa)	7
1.5 Enzalutamide (Xtandi)	80
1.6 Talazoparib (Talzenna)	1
1.7 Docetaxel	25

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

In order to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	
2.2 Olaparib (Lynparza) for prostate cancer	

2.3 Talazoparib (Talzenna) for prostate cancer	
--	--

Q3. How many patients were treated with the following combinations in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

In order to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of medicine	Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT	
3.2 Olaparib (Lynparza) + Abiraterone	

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuporelin, triptorelin, degarelix, flutamide

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

In order to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of medicine	Number patients treated
4.1 Abiraterone	
4.2 Enzalutamide	

NIVOLUMAB

Q5. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
5.1 Nivolumab (Opdivo)	7
5.2 Nivolumab/Relatlimab (Opdualag)	0

Q6. How many patients were treated with Nivolumab (Opdivo) for the following diagnoses in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

In order, to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Diagnosis	Number patients treated
6.1 Malignant melanoma (<i>ICD-10 codes = C43*, C44*, D03*, D485</i>)	
6.2 Lung Cancer (<i>ICD-10 codes = C34*, C780</i>)	
6.3 Mesothelioma (<i>ICD-10 codes = C45*, C384, C782</i>)	
6.4 Renal Cell Carcinoma (<i>ICD-10 codes = C64*, C65*, C790, D410</i>)	
6.5 Oesophageal or Gastro-Oesophageal Junction (<i>ICD-10 codes = C15*</i>)	
6.6 Hodgkin Lymphoma (<i>ICD-10 codes = C81*</i>)	
6.7 Head and Neck Cancer (<i>ICD-10 codes = C00 to C14, C30 to C32, C760, C770</i>)	
6.8 Urothelial Carcinoma (<i>ICD-10 codes = C67*</i>)	

6.9 Colorectal Cancer (*ICD-10 codes = C18 to C20*)

Email: foi.team@southerntrust.hscni.net